Report

influenza diagnostics market

Influenza Diagnostics Market by Test Type (Traditional Diagnostic Test and Molecular Diagnostic Test), by End-user (Hospital, Clinical Laboratories, and Other End-Users), Geography (North America, Europe, APAC, and RoW) - Global Forecast to 2026

pages Pages: 89
tables Tables: 80
charts Charts: 40
country Regions/Countries: 4/9
compaines Companies: 19
enqhours Enquiry Hours: 10
  • Get Free 10% Customization in this Report

COVID - 19

Covid impact updated reports at special price

Influenza is a highly contagious disease caused by the influenza virus attacking the respiratory system - lungs, nose, and throat, which causes illness. This can also lead to the death of the infected person. Influenza diagnostics tests enable to identify the virus in the body.

Research Methodology:

The influenza diagnostics market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology, along with an irreplaceable blend of primary insights. The real-time assessment of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary participants have helped in compiling relevant aspects with realistic parametric estimations for a comprehensive study. The participation share of different categories of primary participants is given below:

Global Influenza Diagnostic Market

The factors pushing the market growth forward are the globally increasing cases of influenza, the given preference for quick diagnosis, an increasing elderly population where the chances of effecting are high, and the advancements in the diagnosis & various tests. In addition, the developing advanced genomics and proteomics technology also fuel the demand. Although some aspects, such as increasing hospital expenses, the discrepancy in the test sensitivity & test specificity, and restricted regulations are hampering the influenza diagnostics market growth. Globally, a major factor affecting the market is the present COVID-19 Pandemic situation. The COVID-19 is also a contagious disease where the virus is attacking the respiratory system, and the influenza tests are increasing due to this pandemic. Influenza Diagnostics Market is predicted to grow at a CAGR of 6.3% during the forecasting period market is expected to grow from $4.0 billion in 2020 to a value of $5.8 billion in 2026.

Influenza Diagnostics Market study is segmented by test type, end-user, and geography.

Based on Test type:

  • Traditional Diagnostic Tests
  • RIDT
  • Viral Culture
  • DFA
  • Serological assays
  • Molecular Diagnostic Tests
  • RT-PCR
  • INNAT
  • TMA
  • LAMP
  • NASBA
  • Other INNAT
  • Other Molecular Tests      

Based on End-User:

  • Hospitals
  • Clinical Laboratories
  • Other End-User                     

Based on Geography:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Majorly, the RIDT diagnostic test in traditional diagnostics test is the most demanding segment based on the test type due to simple usage procedure and the low cost of diagnosis. Moreover, it is significant in the situation of a low-resource setting and also easy to read and less time-consuming procedure. Hence, the RIDT diagnostic test segment has the largest share in the influenza diagnostics market. 

The majority of the influenza diagnostics market share is acquired by the hospital segment based on the end-users. However, the influenza tests are frequently carried by the hospitals due to its complicated nature and also require advanced technology products to carry the influenza diagnosis.

Influenza Diagnostic Market

As per the geographical analysis, the market is segmented by North America, Europe, Asia Pacific, and the rest of the world. Compared to the other regions, North America has acquired the largest share in the market due to the rising incidence of respiratory diseases such as influenza and the increasing demand for the influenza screening test in this region. Asia Pacific region is estimated to have the fastest growth in the market with the rapidly increasing population, which is leading to the spread of contagious diseases while the government is stepping up its initiatives to reduce the spread of contagious diseases.

Globally, the contagious diseases are increasing; hence, the influenza diagnostics enable to identify influenza the most contagious disease. Majorly two factors emphasizing the influenza diagnostics market growth are the increasing elderly population as the old generation is weak, and lack of immunity can cause influenza and the increasing investments in influenza diagnostic research. Somehow, the rising cost of kits and reagents in the influenza diagnostics is the major aspect hindering the market growth.   

The major players who are competing in the influenza diagnostics market are Quidel Corporation, Inc, Abbott Laboratories, Inc., Hologic, Inc, Becton, Dickinson and Company, Danaher CORPORATION, Diasorin sa, Meridian Bioscience, Luminex Corporation, Biomérieux sa, Genmark Diagnostics, Inc, Siemens Healthineers, Thermo Fisher Scientific, Tecan Trading, Sekisui Diagnostics, F. Hoffmann-la Roche AG, SA Scientific, Ltd, Altona Diagnostics GMBH, Coris Bioconcept SPRL and Elitech Group.

Moreover, the advancements in technology and the innovations in developing the quick, precise, and low-cost diagnosis for diseases is the major aspect creating an opportunity for the influenza diagnostics market players. This report gives an in-depth analysis of the drivers, challenges, and opportunities of the influenza diagnostics market.  

  • The analysis based on the segmentation such as test type, end-users and geography is provided in this report
  • This report also provides the strengths and weaknesses, portfolio analysis, capability analysis of the leading players 
  • The report will also help the research organization of influenza diagnostics to support their research in the advancements in the tests for the better diagnosis
  • Quantitative analysis of the market enables users to understand the contribution of the major regions in the market growth.   

1. Executive Summary

2. Industry Outlook

2.1. Industry Overview

2.2. Industry Trends

3. Market Snapshot

3.1. Market Definition

3.2. Market Outlook

3.3. PEST Analysis

3.4. Porter Five Forces

3.5. Related Markets

4. Market characteristics

4.1. Market Evolution

4.2. Market Trends and Impact

4.3. Advantages/Disadvantages of Market

4.4. Regulatory Impact

4.5. Market Offerings

4.6. Market Segmentation

4.7. Market Dynamics

4.7.1. Drivers

4.7.2. Restraints

4.7.3. Opportunities

4.8. DRO - Impact Analysis

5. End-user: Market Size & Analysis

5.1. Overview     

5.2. Traditional Diagnostic Tests

5.2.1. RIDT

5.2.2. Viral Culture

5.2.3. DFA

5.2.4. Serological assays

5.3. Molecular Diagnostic Tests

5.3.1.  RT-PCR

5.3.2.  INNAT

5.3.2.1.   TMA

5.3.2.2.  LAMP

5.3.2.3. NASBA

5.3.2.4. Other INNAT

          5.3.3 Other Molecular Tests        

6. End-User: Market Size & Analysis

6.1. Overview

6.2. Hospitals

6.3. Clinical Laboratories

6.4. Other End-User                   

7. Geography: Market Size & Analysis

7.1. Overview

7.2. North America

7.3. Europe

7.4. Asia Pacific

7.5. Rest of the World

8. Competitive Landscape

8.1. Competitor Comparison Analysis

8.2. Market Developments

8.3. Mergers and Acquisitions, Legal, Awards, Partnerships

8.4. Product Launches and execution

9. Vendor Profiles

9.1. F. HOFFMANN-LA ROCHE AG

9.1.1. Overview

9.1.2. Product Offerings

9.1.3. Geographic Revenue

9.1.4. Business Units

9.1.5. Developments

9.1.6. SWOT Analysis

9.1.7. Business Strategy

9.2. QUIDEL CORPORATION

9.2.1. Overview

9.2.2. Product Offerings

9.2.3. Geographic Revenue

9.2.4. Business Units

9.2.5. Developments

9.2.6. SWOT Analysis

9.2.7. Business Strategy

9.3. THERMO FISHER SCIENTIFIC, INC

9.3.1. Overview

9.3.2. Product Offerings

9.3.3. Geographic Revenue

9.3.4. Business Units

9.3.5. Developments

9.3.6. SWOT Analysis

9.3.7. Business Strategy

9.4. ABBOTT LABORATORIES, INC.

9.4.1. Overview

9.4.2. Product Offerings

9.4.3. Geographic Revenue

9.4.4. Business Units

9.4.5. Developments

9.4.6. SWOT Analysis

9.4.7. Business Strategy

9.5. HOLOGIC, INC

9.5.1. Overview

9.5.2. Product Offerings

9.5.3. Geographic Revenue

9.5.4. Business Units

9.5.5. Developments

9.5.6. SWOT Analysis

9.5.7. Business Strategy

9.6. BECTON, DICKINSON AND COMPANY

9.6.1. Overview

9.6.2. Product Offerings

9.6.3. Geographic Revenue

9.6.4. Business Units

9.6.5. Developments

9.6.6. SWOT Analysis

9.6.7. Business Strategy

9.7. DANAHER CORPORATION

9.7.1. Overview

9.7.2. Product Offerings

9.7.3. Geographic Revenue

9.7.4. Business Units

9.7.5. Developments

9.7.6. SWOT Analysis

9.7.7. Business Strategy

9.8. DIASORIN SA

9.8.1. Overview

9.8.2. Product Offerings

9.8.3. Geographic Revenue

9.8.4. Business Units

9.8.5. Developments

9.8.6. SWOT Analysis

9.8.7. Business Strategy

9.9. MERIDIAN BIOSCIENCE

9.9.1. Overview

9.9.2. Product Offerings

9.9.3. Geographic Revenue

9.9.4. Business Units

9.9.5. Developments

9.9.6. SWOT Analysis

9.9.7. Business Strategy

9.10. LUMINEX CORPORATION

9.10.1. Overview

9.10.2. Product Offerings

9.10.3. Geographic Revenue

9.10.4. Business Units

9.10.5. Developments

9.10.6. SWOT Analysis

9.10.7. Business Strategy

10. Companies to Watch

10.1. BIOMÉRIEUX SA

10.1.1. Overview

10.1.2. Market

10.1.3. Business Strategy

10.2. GENMARK DIAGNOSTICS, INC

10.2.1. Overview

10.2.2. Market

10.2.3. Business Strategy

 

10.3. SIEMENS HEALTHINEERS

10.3.1. Overview

10.3.2. Market

10.3.3. Business Strategy

10.4. TECAN TRADING

10.4.1. Overview

10.4.2. Market

10.4.3. Business Strategy

10.5. SEKISUI DIAGNOSTICS

10.5.1. Overview

10.5.2. Market

10.5.3. Business Strategy

10.6. SA SCIENTIFIC, LTD

10.6.1. Overview

10.6.2. Market

10.6.3. Business Strategy

10.7. ALTONA DIAGNOSTICS GMBH

10.7.1. Overview

10.7.2. Market

10.7.3. Business Strategy

10.8. CORIS BIOCONCEPT SPRL

10.8.1. Overview

10.8.2. Market

10.8.3. Business Strategy

10.9. ELITECH GROUP

10.9.1. Overview

10.9.2. Market

10.9.3. Business Strategy

11. Analyst Opinion

12. Annexure

12.1. Report Scope

12.2. Market Definitions

12.3. Research Methodology

12.3.1. Data Collation and In-house Estimation

12.3.2. Market Triangulation

12.3.3. Forecasting

12.4. Report Assumptions

12.5. Declarations

12.6. Stakeholders

12.7. Abbreviations

TABLE 1.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE, BY TEST TYPE, 2020-2026 (USD BILLION)
TABLE 2.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR TRADITIONAL DIAGNOSTIC TESTS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 3.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR RIDT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 4.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR VIRAL CULTURE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 5.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR DFA, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 6.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR SEROLOGICAL ASSAYS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 7.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR MOLECULAR DIAGNOSTIC TESTS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 8.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR RT-PCR, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 9.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR INNAT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 10.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR TMA, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 11.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR LAMP, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 12.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR OTHER TEST, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 13.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE, BY END-USER, 2020-2026 (USD BILLION)
TABLE 14.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR HOSPITALS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 15.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR CLINICAL LABORATORIES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 16.    GLOBAL INFLUENZA DIAGNOSTICS MARKET VALUE FOR OTHER END-USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 17.    NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 18.    NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 19.    NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 20.    U.S INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 21.    U.S INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 22.    CANADA INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 23.    CANADA INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 24.    EUROPE INFLUENZA DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 25.    EUROPE INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 26.    EUROPE INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 27.    GERMANY INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 28.    GERMANY INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 29.    U.K INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 30.    U.K INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 31.    ROE INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 32.    ROE INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 33.    ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 34.    ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 35.    ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 36.    CHINA INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 37.    INDIA INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 38.    REST OF WORLD INFLUENZA DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
TABLE 39.    REST OF WORLD INFLUENZA DIAGNOSTICS MARKET VALUE FOR TEST TYPE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 40.    REST OF WORLD INFLUENZA DIAGNOSTICS MARKET VALUE FOR END USER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
TABLE 41.    F. HOFFMANN-LA ROCHE AG.: OVERVIEW    
TABLE 42.    F. HOFFMANN-LA ROCHE AG.: STRATEGIC SNAPSHOT    
TABLE 43.    F. HOFFMANN-LA ROCHE AG.: BUSINESS OPPORTUNITIES AND OUTLOOK    
TABLE 44.    F. HOFFMANN-LA ROCHE AG.: TEST TYPE/SERVICE PORTFOLIO
TABLE 45.    QUIDEL CORPORATION: OVERVIEW    
TABLE 46.    QUIDEL CORPORATION: STRATEGIC SNAPSHOT    
TABLE 47.    QUIDEL CORPORATION: BUSINESS OPPORTUNITIES AND OUTLOOK    
TABLE 48.    QUIDEL CORPORATION: TEST TYPE/SERVICE PORTFOLIO
TABLE 49.    THERMO FISHER SCIENTIFIC, INC: OVERVIEW    
TABLE 50.    THERMO FISHER SCIENTIFIC, INC: STRATEGIC SNAPSHOT    
TABLE 51.    THERMO FISHER SCIENTIFIC, INC: BUSINESS OPPORTUNITIES AND OUTLOOK    
TABLE 52.    THERMO FISHER SCIENTIFIC, INC: TEST TYPE/SERVICE PORTFOLIO
TABLE 53.    ABBOTT LABORATORIES, INC..: OVERVIEW    
TABLE 54.    ABBOTT LABORATORIES, INC..: STRATEGIC SNAPSHOT    
TABLE 55.    ABBOTT LABORATORIES, INC..: BUSINESS OPPORTUNITIES AND OUTLOOK    
TABLE 56.    ABBOTT LABORATORIES, INC..: TEST TYPE/SERVICE PORTFOLIO
TABLE 57.    HOLOGIC, INC: OVERVIEW    
TABLE 58.    HOLOGIC, INC: STRATEGIC SNAPSHOT    
TABLE 59.    HOLOGIC, INC: BUSINESS OPPORTUNITIES AND OUTLOOK    
TABLE 60.    HOLOGIC, INC: TEST TYPE/SERVICE PORTFOLIO
TABLE 61.    BECTON, DICKINSON AND COMPANY.: OVERVIEW    
TABLE 62.    BECTON, DICKINSON AND COMPANY.: STRATEGIC SNAPSHOT    
TABLE 63.    BECTON, DICKINSON AND COMPANY.: BUSINESS OPPORTUNITIES AND OUTLOO    
TABLE 64.    BECTON, DICKINSON AND COMPANY.: TEST TYPE/SERVICE PORTFOLIO
TABLE 65.    DANAHER CORPORATION: OVERVIEW    
TABLE 66.    DANAHER CORPORATION: STRATEGIC SNAPSHOT    
TABLE 67.    DANAHER CORPORATION: BUSINESS OPPORTUNITIES AND OUTLOOK    
TABLE 68.    DANAHER CORPORATION: TEST TYPE/SERVICE PORTFOLIO
TABLE 69.    DIASORIN SA: OVERVIEW    
TABLE 70.    DIASORIN SA: STRATEGIC SNAPSHOT    
TABLE 71.    DIASORIN SA: BUSINESS OPPORTUNITIES AND OUTLOOK    
TABLE 72.    DIASORIN SA: TEST TYPE/SERVICE PORTFOLIO
TABLE 73.    MERIDIAN BIOSCIENCE: OVERVIEW    
TABLE 74.    MERIDIAN BIOSCIENCE: STRATEGIC SNAPSHOT    
TABLE 75.    MERIDIAN BIOSCIENCE: BUSINESS OPPORTUNITIES AND OUTLOOK    
TABLE 76.    MERIDIAN BIOSCIENCE: TEST TYPE/SERVICE PORTFOLIO
TABLE 77.    LUMINEX CORPORATION.: OVERVIEW    
TABLE 78.    LUMINEX CORPORATION.: STRATEGIC SNAPSHOT    
TABLE 79.    LUMINEX CORPORATION.: BUSINESS OPPORTUNITIES AND OUTLO    
TABLE 80.    LUMINEX CORPORATION.: TEST TYPE/SERVICE PORTFOLIO

Research Framework

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting
Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources

Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources

Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

outicon

Influenza Diagnostics Market by Test Type (Traditional Diagnostic Test and Molecular Diagnostic Test), by End-user (Hospital, Clinical Laboratories, and Other End-Users), Geography (North America, Europe, APAC, and RoW) - Global Forecast to 2026
Interested in this report?
Get your FREE sample now!

Select User License

$

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer 10% worth of FREE customization at the time of purchase

Speak to our analyst
Related Reports